CHR-6494 is primarily investigated for its potential in cancer therapy, particularly as an inhibitor of histone deacetylase (HDAC) enzymes. By targeting HDACs, it plays a role in regulating gene expression, which can lead to the suppression of tumor growth and the induction of apoptosis in cancer cells. Its application is significant in research focused on developing treatments for various cancers, including hematological malignancies and solid tumors. Additionally, it is studied for its potential to enhance the efficacy of other anticancer agents when used in combination therapies.